ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma
ARID1A deficiency may be an independent prognostic factor and attenuates the response to EGFR-TKIs in patients with EGFR-mutant LUAD. In addition, loss of ARID1A expression confers resistance to EGFR-TKI by activating the EGFR/AKT/mTOR signalling axis.
Authors
- Xingfa Huo (ORCID: https://orcid.org/0000-0002-7302-464X)
- Guangming Fu (ORCID: https://orcid.org/0000-0001-8726-0523)
- Na Zhou (ORCID: https://orcid.org/0000-0003-2656-7948)
- Guanqun Wang (ORCID: https://orcid.org/0000-0003-1301-624X)
- Xueqin Duan
- Xiaochun Zhang
- Helei Hou
- Fangfang Yang (ORCID: https://orcid.org/0000-0003-3521-6947)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.3389/fphar.2025.1582005
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shandong Province